AN OPEN-LABEL, CROSSOVER STUDY OF ALTERNATIVE DIETARY THERAPIES FOR GLYCOGEN STO

糖原 STO 替代饮食疗法的开放标签、交叉研究

• 批准号: 7380765
• 负责人: DAVID A WEINSTEIN
• 金额: $ 0.66万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7380765
• 关键词: OPEN; LABEL; CROSSOVER; STUDY; ALTERNATIVE

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Aims: 1. To determine the efficacy of three new glucose sources that have a lower glycemic index then the currently used cornstarch. Hypothesis - It is expected that the lower glycemic index therapies will maintain a blood sugar level above 70 mg/dL for a greater amount of time than the traditional cornstarch therapy. 2. To determine the metabolic control of each glucose source. Hypothesis ¿ Due to the lower glycemic index of the new glucose sources it is anticipated that they will deliver better metabolic control. 3. To assess the adverse side effect profile of each of the products. Hypothesis - It is projected that the new glucose sources will produce no greater adverse side effects than the traditional Argo cornstarch. Some foods contain sugars that are undigestable by human enzymes and resultantly may be digested by bacteria in the colon which produces gas and may cause discomfort. The three carbohydrate sources being explored are low in undigestable sugars and should cause minimal discomfort.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。目的： 1. 确定三种新葡萄糖源的功效，这些葡萄糖源的血糖指数低于目前使用的玉米淀粉。 假设 - 预计较低血糖指数疗法将比传统玉米淀粉疗法更长时间地将血糖水平维持在 70 mg/dL 以上。 2. 确定每种葡萄糖来源的代谢控制。假设 - 由于新葡萄糖源的血糖指数较低，预计它们将提供更好的代谢控制。 3. 评估每种产品的不良副作用。 假设 - 预计新的葡萄糖来源不会比传统的 Argo 玉米淀粉产生更大的副作用。有些食物含有人体酶无法消化的糖，因此可能会被结肠中的细菌消化，产生气体并可能引起不适。正在探索的三种碳水化合物来源的不可消化糖含量较低，应该不会引起任何不适。